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Patients with unstable angina and intracoronary thrombus are more likely
to have lower procedural success, higher abrup1 closure risk, and worse in-
hospital clinical outcome. Patients with unstable angina and preprocedural
intracoronary thrombus represent a high risk group for which new strategies
need to be developed to improve the outcome of percutaneous interven-
tions.
Performance of Coronary Angioplasty in Patients
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Results Men Women p value
Angio Reference (mm) 350 3.29 NS
Ultrasound Reference (mm) 337 2.85 0001
Balloon Size (mm) 348 3.27 010
Balloon/Angio RatiO 1.00 1.02 NS
BalloonlUltrasound Ratio 1.06 1.17 005
Intravascular Ultrasound Evidence of Significant
Oversizing of Angioplasty Balloons in Female
Patients
David J. Moliterno, Anthony C. De Franco, E. Murat Tuzcu, Stephen G. Ellis, David
S. Eccleston, Russell E. Raymond, Patrick L. Whitlow, Steven E. Nissen. Cleveland
Clinic, Cleveland, OH
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To gain insight into the strategies and factors influencing the performance of
percutaneous transluminal coronary angioplasty (PTCA) in patients (pts) with
multivessel coronary artery disease, the procedures of the 915 pts assigned
to PTCA in BARI were examined. Within this group, 3,427 angiographically
significant (>50% diameter reduction) lesions were identified. The majority
of pts had two to six angiographically significant lesions. PTCA was intended
for 63.1 % of angiographically significant lesions and was attempted in 92.7%
of the lesions for which it was intended. Multilesion PTCA was performed
in 77.5% of pts and multivessel PTCA in 69.7%. Staging of the PTCA proce-
dures was performed in 17.5% of pts. The number of lesions attempted per
pt ranged from 1-9 with most pts (72.6%) having 2-4 lesions attempted. Of
lesions present, those between 50-95% were most frequently attempted.
Lesions of 99-100% severity and those less than 50% were less likely to be
attempted. Other factors significantly Ip < 0.05) associated with attempting
lesions included proximal vessel location, classification of a lesion as being a
"culprit" or "clinically significant" or type A or B complexity. Lesions in arteries
supplying a small territory or non-viable myocardium were rarely attempted.
Thus in pts with extensive multivessel CAD, PTCA is applied judiciously and
according to a strategy based on individual pt and lesion assessment. An-
giographic anatomic characteristics and the clinical impact of the lesion are
the most influential factors.
Objectives: Although women may have an increased risk of complications
following interventions, the etiology of this gender-related effect remains un-
certain. While oversizing of angioplasty balloons is associated with increased
complications, no angiographic data have demonstrated inappropriate bal-
loon sizing in women.
Methods: We performed intravascular ultrasound and quantitative angiog-
raphy in 124 patients (101 males, 23 females) before and after coronary bal-
loon angioplasty. In 51 patients, balloon angioplasty was the primary ther-
apy, while in 73, balloon dilatation was performed as an adjunct to rotational
or directional atherectomy. Separate core laboratories, blinded to outcome,
measured angiographic and ultrasound dimensions in reference segments
and target lesions.
These important differences in the ratio of balloon to ultrasound vessel
diameter are partially explained by a greater plaque burden at reference sites
in women (ultrasound area reduction of 43.7% vs. 37.6%).
Conclusions: Although balloons were appropriately sized in women
when compared to angiographic diameter, significant oversizing of balloon
catheters in women was apparent when compared to ultrasound reference
segment dimensions. These findings have important clinical implications for
coronary interventions in women.
Effect of Non-target Lesion Events on the
Predictive Value of 6-Month Angiography for Late
(12 Month) Clinical Outcome After PTCA
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Center, Washington, DC
To determine whether the observed discordance between late angiographic
and clinical outcomes in clinical restenosis studies (European angiopeptin:
clinical but not angiographic benefit; CAVEAT: angiographic but not clini-
cal benefit) is affected by the occurrence of late non-target lesion events
(death, myocardial infarction [MI). or remote-site revascularization), we re-
viewed the outcomes of 1061 successfully-treated patients «50% stenosis
and no death, MI, CABG or repeat PTCA <14 days) enrolled in the American
"Pulse Spray" Mini-Urokinase Infusion for
Recanalization of Recently Occluded Saphenous
Vein Grafts
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The outcome of percutaneous coronary interventions in patients with prepro-
cedural angiographic evidence of thrombus at the target lesion is uncertain.
Detailed angiographic and clinical data were prospectively collected from
2,164 patients enrolled in 3 clinical trials with stable and unstable angina un-
dergoing non-emergency percutaneous coronary interventions. Procedural
success «50% final visual stenosis without death or emergency CABGl and
the presence of preprocedural intracoronary thrombus, defined as a discrete
filling defect at the target lesion, were determined by core laboratory review.
Patient age, prior cardiac history, cardiovascular risk factors, and severity of
disease were well matched between patients with and without thrombus.
Outcomes with 95% confidence intervals were:
Infusions of 1,000,000-6,000,000 U of urokinase over 17-70 hours have
been shown to successfully recanalize recently (2-8 weeks) occluded saphe-
nous vein grafts, however, major bleeding complications are common. These
bleeding complications are often related to the systemic fibrinolytic state in-
duced by the large dose of urokinase given during these infusions. In ad-
dition, these infusions often place a strain on the cardiac catheterization
laboratory scheduling due to their lengthy nature. "Pulse spray" infusions
of urokinase have been shown to successfully recanalize peripheral arterial
and graft occlusions using a much lower dose of urokinase over a shorter
period of time. This procedure requires the placement of a multiple side hole
infusion catheter directly in contact with the occlusion followed by frequent
injections or "sprays" of small doses of urokinase until recanalization is com-
plete. We sought to determine if "pulse spray" mini-urokinase infusion would
shorten the duration and decrease the dose of urokinase infusion required
to successfully recanalize recently occluded saphenous vein grafts (SVG).
Methods: Five patients underwent "pulse spray" mini-urokinase infusions
during the last six months. The mean age was 72.4. All had unstable angina.
The mean age of the occlusion was 3.4 weeks (range 2-6). The target vessel
was as follows: SVG-.LCx (3), SVG-.RCA (1), SVG-.LAD (1). Standard an-
gioplasty guiding catheters and guidewires were used. A Roubin® infusion
catheter was used to locally spray the urokinase. Heparin was administered
to maintain the ACT> 300s during the procedure.
Results: All SVG's were successfully recanalized using the "pulse spray"
mini-urokinase infusion. The mean duration of infusion was 52 minutes
(range 40-60). The mean dose of urokinase was 650,000 U (range 500,000-
750,000 U). All residual SVG stenoses then underwent successful PTCA. No
major ischemic (death, CABG, Mil or bleeding complications (bleeding re-
quiring transfusion, vascular repairl occurred.
Conclusion: Thus, "pulse spray" mini urokinase infusions can successfully
recanalize recently occluded saphenous vein grafts using a much lower dose
of urokinase over a shorter period of time than has previously been reported.
Interestingly, major bleedin'g complications also appear to be reduced. A
larger randomized trial will be required to fully evaluate this technique.
Outcomes Stable Angina Unstable Angina
No Thrombus Thrombus
(n ~ 450) (n ~ 1,476) (n ~ 238)
Procedural Success 87% (84-90%) 85% 183-87%) 80% 175-85%)
Abrupt Closure 4% ( 2- 6%) 6%1 5- 7%) 11%17-15%)
In-Hospital
Death <1% 1% 0
MI 5% 3% 5%
CABG 2% 4% 9%
Repeat PTCA 3% 3% 2%
Composite Outcome 6%14-8%) 8% 17-9%) 12%18-16%)
Six-Month Outcome 27% (23-31 %) 29% (27-31 %) 34% 128-40%)
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